Management of Therapy‑Related Acute Myeloid Leukemia in Multiple Myeloma Patients

Diagnosis and Risk Assessment

Comprehensive diagnostic workup—including peripheral blood and bone‑marrow aspirate morphology, cytochemistry, immunophenotyping, and cytogenetic analysis—is required before initiating therapy in patients with suspected therapy‑related AML/MDS. 1
Coagulation screening should be performed prior to central‑line placement to reduce procedural bleeding risk. 1, 2
Early HLA typing is recommended for patients who may be candidates for allogeneic stem‑cell transplantation, including potential family donors. 1, 2

Standard induction chemotherapy consists of an anthracycline combined with cytarabine, reflecting the consensus across AML guideline bodies. 1, 3, 4, 2, 5, 6, 7, 8
Initiation of chemotherapy should be delayed until adequate diagnostic specimens have been obtained to guide treatment planning. 1, 3, 4
In cases of marked leukocytosis, emergency leukapheresis may be required before induction chemotherapy to control tumor burden. 1, 3, 4, 7
Lack of response after one to two induction cycles defines refractory disease and prompts consideration of alternative strategies. 1, 3, 4, 5, 8

Patients achieving remission should receive one or more cycles of consolidation therapy to deepen and maintain response. 9, 1, 3, 6
Allogeneic stem‑cell transplantation is advised for eligible patients with HLA‑matched sibling or unrelated donors, especially given the high‑risk cytogenetic profile typical of therapy‑related disease. 1, 3, 4, 2, 5, 7, 8
For patients with favorable‑risk features, chemotherapy alone—preferably incorporating high‑dose cytarabine—may be sufficient, although this approach is less common in therapy‑related AML. 1, 3, 4, 2, 6, 7, 8

Individuals with poor performance status or significant comorbidities should be managed with best‑supportive care rather than intensive chemotherapy. 9, 1, 3, 4, 2, 8

Early mortality is high; several series report deaths within the first month after diagnosis of therapy‑related AML/MDS. 10

Management should be performed in multidisciplinary centers equipped with hematology/oncology services, a bone‑marrow transplant unit, infectious‑disease support, and robust transfusion capabilities. 9, 1, 3, 4, 2, 5, 8

Evaluation of treatment response requires serial clinical assessments, complete blood counts, and repeat bone‑marrow aspirates. 9, 1, 3, 4, 5, 6, 7, 8
Remission criteria for AML include normal marrow cellularity, morphologically normal hematopoiesis, and blast percentage below 5 %. 9, 1, 3, 4, 5, 6, 7, 8
During induction‑related aplasia, bone‑marrow aspirates should be used to detect early response or persistent blasts, guiding subsequent therapeutic decisions. 9, 1, 3, 4, 5, 6, 7, 8